Suppr超能文献

局部晚期及淋巴结阳性膀胱癌患者的保膀胱放射治疗。

Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer.

作者信息

Carriere Patrick, Alhalabi Omar, Gao Jianjun, Mohamad Osama, Campbell Matthew T, Shah Amishi, Goswami Sangeeta, Bree Kelly, Lee Byron, Navai Neema, Mok Henry, Mayo Lauren, Guo Charles, Nguyen Quynh, McGuire Sean, Park Ryan, Shah Shalin, Hoffman Karen, Frank Steven, Tang Chad, Choi Seungtaek, Kamat Ashish, Hassanzadeh Comron

机构信息

Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Clin Transl Radiat Oncol. 2024 Sep 28;49:100866. doi: 10.1016/j.ctro.2024.100866. eCollection 2024 Nov.

Abstract

PURPOSE

Trimodality therapy for muscle-invasive bladder cancer (MIBC) yields similar oncologic outcomes compared to radical cystectomy in appropriately selected patients; however, data regarding locally advanced MIBC (LA-MIBC) is limited. We explored our experience with LA-MIBC undergoing radiation therapy (RT).

METHODS

We retrospectively identified 30 patients from an institutional prospectively collated database with non-metastatic, LA-MIBC. Patients with T3-4 N0 or T2-4 N + treated from 2012 to 2022 with definitive-intent RT, who were not candidates for cystectomy were included. Kaplan-Meier analysis was used to estimate time-to-event outcomes, and multivariate analyses were conducted using Cox proportional hazards modeling.

RESULTS

43 % had T3N0 disease, 30 % had T4N0 disease, and 27 % had node positive disease.. Neoadjuvant chemotherapy/systemic therapy was administered in 63 % of patients. Median dose and fractionation of RT was 60 Gy in 30 fractions. 23 % of patients received hypofractionated RT, 57 % received nodal RT.At a median follow-up of 20 (range, 1-75) months after RT, estimated 1- and 2-year OS was 73 % and 61 %, respectively. Estimated 1-year progression-free survival was 50 %. Local bladder failure was a component of progression in 17 % of patients, and all local bladder failure events occurred within the first 12 months following RT. Lymph node or distant metastases occurred in 23 % of patients. Estimated 1-year OS was 83 % with pure urothelial histology but only 58 % with variant histology (P = 0.001). Late grade 3 + GU and GI toxicity occurred in 7 % and 5 % of patients, respectively.

CONCLUSIONS

In this cohort with LA-MIBC treated with RT, distant failures predominate, local failures are less common, and toxicity was minimal. Survival outcomes remain encouraging for RT in this challenging patient population. Further investigation is warranted to identify biomarkers for patient selection and strategies to improve distant control.

摘要

目的

对于经适当选择的患者,肌肉浸润性膀胱癌(MIBC)的三联疗法与根治性膀胱切除术相比,肿瘤学结局相似;然而,关于局部晚期MIBC(LA - MIBC)的数据有限。我们探讨了LA - MIBC患者接受放射治疗(RT)的经验。

方法

我们从一个机构前瞻性整理的数据库中回顾性地识别出30例非转移性LA - MIBC患者。纳入2012年至2022年接受根治性意图RT治疗、不适合膀胱切除术的T3 - 4 N0或T2 - 4 N +患者。采用Kaplan - Meier分析估计事件发生时间结局,并使用Cox比例风险模型进行多变量分析。

结果

43%的患者患有T3N0疾病,30%患有T4N0疾病,27%患有淋巴结阳性疾病。63%的患者接受了新辅助化疗/全身治疗。RT的中位剂量和分割为60 Gy,分30次。23%的患者接受了大分割RT,57%接受了淋巴结RT。RT后中位随访20(范围1 - 75)个月,估计1年和2年总生存率分别为73%和61%。估计1年无进展生存率为50%。17%的患者进展包括局部膀胱失败,所有局部膀胱失败事件均发生在RT后的前12个月内。23%的患者发生淋巴结或远处转移。纯尿路上皮组织学患者的估计1年总生存率为83%,但组织学变异患者仅为58%(P = 0.001)。7%和5%的患者分别发生了晚期3级及以上泌尿生殖系统和胃肠道毒性。

结论

在这个接受RT治疗的LA - MIBC队列中,远处失败占主导,局部失败较少见,且毒性最小。对于这个具有挑战性的患者群体,RT的生存结局仍然令人鼓舞。有必要进一步研究以确定用于患者选择的生物标志物和改善远处控制的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebbf/11472623/bc8405fc3cc2/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验